Trial
NCT03285308
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Allergan
Collaborators
—
Condition
Gastroparesis
Intervention
Placebo
Why stopped
The Relamorelin program is being terminated solely based on a business decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-29